TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EOE)

摘要

Embodiments of the application involve a formulation of Fluticasone Propionate in the form of a suspension, gel or dry powder comprising Fluticasone Propionate, Fluticasone Furcate, Micronized Fluticasone Propionate or Micronized Fluticasone Furcate or other corticosteroids. Additional pharmaceutical components of the formulation may allow for the adherence and duration of the active ingredient to the inflamed esophageal tissues. The resulting medication formulation is then targeted with a drug delivery device and applied directly to the oropharynx bypassing the oral cavity altogether. The medication then flows down the back of the throat to the esophagus. By passing the oral cavity prevents the corticosteroid drug from being absorbed into the bloodstream through oral cavity tissues, helping to prevent harmful side effects. Additional side effects are avoided by using the medication Fluticasone, which exhibits exceptionally low gastrointestinal absorption.